See more : A&D HOLON Holdings Company Limited (7745.T) Income Statement Analysis – Financial Results
Complete financial analysis of Organovo Holdings, Inc. (ONVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Organovo Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shin Nippon Air Technologies Co., Ltd. (1952.T) Income Statement Analysis – Financial Results
- Tertiary Minerals plc (TYM.L) Income Statement Analysis – Financial Results
- Alpha and Omega Semiconductor Limited (AOSL) Income Statement Analysis – Financial Results
- Eco Oro Minerals Corp. (EOM.CN) Income Statement Analysis – Financial Results
- Hayden Hall, Inc. (HYDN) Income Statement Analysis – Financial Results
Organovo Holdings, Inc. (ONVO)
About Organovo Holdings, Inc.
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 109.00K | 370.00K | 1.50M | 0.00 | 2.20M | 3.09M | 4.60M | 4.23M | 1.48M | 571.00K | 379.00K | 1.20M | 0.00 |
| Cost of Revenue | 0.00 | 293.00K | 142.00K | 41.00K | 328.00K | 482.00K | 1.03M | 956.00K | 18.01M | 12.92M | 7.97M | 4.34M | 0.00 |
| Gross Profit | 109.00K | 77.00K | 1.36M | -41.00K | 1.87M | 2.61M | 3.57M | 3.27M | -16.53M | -12.35M | -7.60M | -3.14M | 0.00 |
| Gross Profit Ratio | 100.00% | 20.81% | 90.53% | 0.00% | 85.06% | 84.41% | 77.62% | 77.40% | -1,114.30% | -2,162.87% | -2,003.96% | -262.32% | 0.00% |
| Research & Development | 5.50M | 8.89M | 3.32M | 1.10M | 5.28M | 14.75M | 17.96M | 19.55M | 18.01M | 12.92M | 7.97M | 3.44M | 0.00 |
| General & Administrative | 9.64M | 9.09M | 9.63M | 15.71M | 17.15M | 0.00 | 0.00 | 22.30M | 22.12M | 17.95M | 0.00 | 0.00 | 120.09K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.64M | 9.09M | 9.63M | 15.71M | 17.15M | 15.13M | 20.89M | 22.30M | 22.12M | 17.95M | 13.05M | 7.08M | 120.09K |
| Other Expenses | 0.00 | 128.00K | 28.00K | 15.00K | 909.00K | 0.00 | -12.00K | 0.00 | 0.00 | 0.00 | 0.00 | -9.00K | 120.09K |
| Operating Expenses | 15.20M | 18.10M | 12.98M | 16.83M | 23.34M | 29.88M | 38.84M | 41.85M | 40.13M | 30.87M | 21.03M | 10.52M | 120.09K |
| Cost & Expenses | 15.20M | 18.10M | 12.98M | 16.83M | 23.67M | 30.37M | 39.87M | 42.81M | 40.13M | 30.87M | 21.03M | 10.52M | 120.09K |
| Interest Income | 405.00K | 454.00K | 8.00K | 15.00K | 594.00K | 705.00K | 478.00K | 198.00K | 88.00K | 32.00K | 18.00K | 5.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 8.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 13.00K | 1.09M | 0.00 |
| Depreciation & Amortization | 280.00K | 293.00K | 142.00K | 41.00K | 1.14M | 983.00K | 1.27M | 1.15M | 815.00K | 472.00K | 387.00K | 195.00K | 2.28K |
| EBITDA | -14.81M | -17.44M | -11.34M | -16.78M | -20.33M | -26.29M | -34.00M | -37.43M | -37.83M | -29.61M | -25.45M | -26.00M | -1.12M |
| EBITDA Ratio | -13,583.49% | -4,718.38% | -755.80% | 0.00% | -954.96% | -848.63% | -738.82% | -880.09% | -2,544.84% | -5,217.69% | -5,341.42% | -940.52% | 0.00% |
| Operating Income | -15.09M | -17.73M | -11.48M | -16.83M | -21.48M | -27.27M | -35.27M | -38.58M | -38.64M | -30.30M | -20.65M | -9.32M | -147.82K |
| Operating Income Ratio | -13,840.37% | -4,792.16% | -765.27% | 0.00% | -977.91% | -882.37% | -766.26% | -911.94% | -2,605.73% | -5,305.95% | -5,448.28% | -778.53% | 0.00% |
| Total Other Income/Expenses | 417.00K | 474.00K | 33.00K | 2.00K | 2.77M | 642.00K | 470.00K | 151.00K | 71.00K | 215.00K | -5.20M | -34.23M | -1.19M |
| Income Before Tax | -14.67M | -17.26M | -11.45M | -16.82M | -18.71M | -26.63M | -34.80M | -38.42M | -38.57M | -30.08M | -25.85M | -43.55M | -147.82K |
| Income Before Tax Ratio | -13,457.80% | -4,664.05% | -763.07% | 0.00% | -851.91% | -861.60% | -756.05% | -908.37% | -2,600.94% | -5,268.30% | -6,820.05% | -3,638.51% | 0.00% |
| Income Tax Expense | 2.00K | 2.00K | 2.00K | 2.00K | 2.00K | 3.00K | 2.00K | 23.00K | 3.00K | -215.00K | 5.20M | 34.23M | 27.72K |
| Net Income | -14.67M | -17.26M | -11.45M | -16.83M | -18.71M | -26.64M | -34.80M | -38.45M | -38.58M | -30.08M | -25.85M | -43.55M | -147.82K |
| Net Income Ratio | -13,459.63% | -4,664.59% | -763.20% | 0.00% | -852.00% | -861.70% | -756.09% | -908.91% | -2,601.15% | -5,268.30% | -6,820.05% | -3,638.51% | 0.00% |
| EPS | -1.60 | -1.98 | -1.32 | -2.44 | -2.89 | -4.62 | -6.49 | -7.87 | -8.57 | -7.55 | -7.07 | -13.03 | -0.04 |
| EPS Diluted | -1.60 | -1.98 | -1.32 | -2.44 | -2.89 | -4.62 | -6.49 | -7.87 | -8.35 | -7.55 | -7.07 | -20.19 | -0.04 |
| Weighted Avg Shares Out | 9.14M | 8.71M | 8.70M | 6.90M | 6.48M | 5.77M | 5.36M | 4.89M | 4.50M | 3.98M | 3.66M | 3.34M | 3.60M |
| Weighted Avg Shares Out (Dil) | 9.14M | 8.71M | 8.70M | 6.90M | 6.48M | 5.77M | 5.36M | 4.89M | 4.62M | 3.98M | 3.66M | 2.16M | 3.60M |
The Top Stocks To Buy Now
Individual stock picking is increasingly important. Continue to concentrate on healthcare and technology. Here are the top stocks to buy now.
Insights on the Worldwide 3D Printing Industry to 2030 - New Product Launches, Partnerships, Investments and M&A - ResearchAndMarkets.com
The "Global 3D Printing Market 2020-2030 by Component (3D Printers, Consumables, Software, Service), Process and Technology, Use Type (Commercial, Personal), Application, Industry Vertical, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com'
Head to Head Review: Sutro Biopharma (NASDAQ:STRO) and Organovo (NASDAQ:ONVO)
Organovo (NASDAQ:ONVO) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Analyst...
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test)...
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ...
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) …
Contrasting Organovo (NASDAQ:ONVO) & Fate Therapeutics (NASDAQ:FATE)
Organovo (NASDAQ:ONVO) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation. Insider...
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) …
Source: https://incomestatements.info
Category: Stock Reports